SG11202011066XA - C-mannoside compounds useful for the treatment of urinary tract infections - Google Patents

C-mannoside compounds useful for the treatment of urinary tract infections

Info

Publication number
SG11202011066XA
SG11202011066XA SG11202011066XA SG11202011066XA SG11202011066XA SG 11202011066X A SG11202011066X A SG 11202011066XA SG 11202011066X A SG11202011066X A SG 11202011066XA SG 11202011066X A SG11202011066X A SG 11202011066XA SG 11202011066X A SG11202011066X A SG 11202011066XA
Authority
SG
Singapore
Prior art keywords
treatment
urinary tract
compounds useful
tract infections
mannoside compounds
Prior art date
Application number
SG11202011066XA
Other languages
English (en)
Inventor
Michael Joseph Bishop
Vincent J Colandrea
Yuehu Li
Eugene L Stewart
Iulia Strambeanu
Katherine Louisa Widdowson
James Walter Janetka
Laurel Kathryn Mcgrane
Original Assignee
Glaxosmithkline Ip Dev Ltd
Fimbrion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Fimbrion Therapeutics Inc filed Critical Glaxosmithkline Ip Dev Ltd
Publication of SG11202011066XA publication Critical patent/SG11202011066XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202011066XA 2018-07-10 2019-07-08 C-mannoside compounds useful for the treatment of urinary tract infections SG11202011066XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695993P 2018-07-10 2018-07-10
US201862755588P 2018-11-05 2018-11-05
PCT/IB2019/055806 WO2020012336A1 (en) 2018-07-10 2019-07-08 C-mannoside compounds useful for the treatment of urinary tract infections

Publications (1)

Publication Number Publication Date
SG11202011066XA true SG11202011066XA (en) 2021-01-28

Family

ID=67957191

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011066XA SG11202011066XA (en) 2018-07-10 2019-07-08 C-mannoside compounds useful for the treatment of urinary tract infections

Country Status (24)

Country Link
US (3) US11111262B2 (hr)
EP (1) EP3820856B9 (hr)
JP (2) JP7309862B2 (hr)
KR (1) KR20210031682A (hr)
CN (1) CN112334455B (hr)
AU (1) AU2019301946B2 (hr)
BR (1) BR112021000370A2 (hr)
CA (1) CA3105940A1 (hr)
CL (1) CL2021000033A1 (hr)
DK (1) DK3820856T3 (hr)
ES (1) ES2928634T3 (hr)
HR (1) HRP20221381T1 (hr)
HU (1) HUE060140T2 (hr)
IL (1) IL279993B2 (hr)
LT (1) LT3820856T (hr)
MX (1) MX2021000340A (hr)
PH (1) PH12020551905A1 (hr)
PL (1) PL3820856T3 (hr)
PT (1) PT3820856T (hr)
RS (1) RS63712B1 (hr)
SG (1) SG11202011066XA (hr)
TW (1) TWI821328B (hr)
UY (1) UY38293A (hr)
WO (1) WO2020012336A1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105940A1 (en) * 2018-07-10 2020-01-16 Glaxosmithkline Intellectual Property Development Limited C-mannoside compounds useful for the treatment of urinary tract infections
WO2020191091A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
CN113461753B (zh) 2020-03-31 2023-05-23 郑计岳 2-炔基甘露糖衍生物及其应用
WO2021242581A1 (en) 2020-05-29 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
DK0730601T3 (da) 1993-11-18 2005-06-06 Univ Washington Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner
EP1192038B1 (en) 1999-06-28 2003-11-05 Lear Corporation Method of forming a blow-molded plastic part having a living hinge
WO2001010386A2 (en) 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
EP1303256B1 (en) 2000-06-09 2009-01-07 Baylor College of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
AU2003274127A1 (en) 2003-10-08 2005-04-21 Innovaprotean, S.L. Compounds for the treatment of diseases associated with the formation of amyloid fibrils
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
AU2010333017B2 (en) 2009-12-14 2016-06-16 University Of Basel Mannose derivatives as antagonists of bacterial adhesion
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
US20130261077A1 (en) 2012-03-07 2013-10-03 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
EP2690105A1 (en) 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
US20140107049A1 (en) 2012-10-04 2014-04-17 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
PL2935302T3 (pl) 2012-12-18 2018-12-31 Vertex Pharmaceuticals Incorporated Pochodne mannozy do leczenia infekcji bakteryjnych
CA2905019C (en) 2013-03-12 2021-07-06 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014194270A1 (en) 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections
JP6961572B2 (ja) 2015-08-05 2021-11-05 アンテローム 付着性大腸菌と関連する病状の処置に有用なマンノース誘導体
JP2019508504A (ja) * 2016-03-11 2019-03-28 フィンブリオン セラピューティックス， インコーポレイテッドＦｉｍｂｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 疾病の処置に有用なｃ−グリコシド化合物
CA3018345A1 (en) 2016-03-23 2017-09-28 Fimbrion Therapeutics, Inc. Mannose-derived antagonists of fimh useful for treating disease
AU2018351471A1 (en) 2017-10-16 2020-05-07 Enterome New tools for assessing FimH blockers therapeutic efficiency
CA3105940A1 (en) * 2018-07-10 2020-01-16 Glaxosmithkline Intellectual Property Development Limited C-mannoside compounds useful for the treatment of urinary tract infections

Also Published As

Publication number Publication date
RS63712B1 (sr) 2022-11-30
DK3820856T3 (da) 2022-10-24
AU2019301946B2 (en) 2022-03-31
US11697665B2 (en) 2023-07-11
IL279993B1 (en) 2023-09-01
JP7309862B2 (ja) 2023-07-18
EP3820856B9 (en) 2023-07-12
JP2022511594A (ja) 2022-02-01
JP7483820B2 (ja) 2024-05-15
US20230287028A1 (en) 2023-09-14
TWI821328B (zh) 2023-11-11
CN112334455A (zh) 2021-02-05
UY38293A (es) 2020-05-29
WO2020012336A1 (en) 2020-01-16
HRP20221381T1 (hr) 2023-01-06
HUE060140T2 (hu) 2023-02-28
PT3820856T (pt) 2022-10-17
PL3820856T3 (pl) 2022-12-19
BR112021000370A2 (pt) 2021-04-06
CL2021000033A1 (es) 2021-07-30
PH12020551905A1 (en) 2021-06-21
ES2928634T3 (es) 2022-11-21
CN112334455B (zh) 2022-07-01
TW202019893A (zh) 2020-06-01
JP2022191325A (ja) 2022-12-27
MX2021000340A (es) 2021-03-25
IL279993A (en) 2021-03-01
AU2019301946A1 (en) 2020-11-26
EP3820856A1 (en) 2021-05-19
EP3820856B1 (en) 2022-08-31
US11111262B2 (en) 2021-09-07
US20210395287A1 (en) 2021-12-23
CA3105940A1 (en) 2020-01-16
KR20210031682A (ko) 2021-03-22
IL279993B2 (en) 2024-01-01
LT3820856T (lt) 2022-11-10
US20210017212A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
IL272766A (en) A nesting pump to increase the removal of urine from the urinary tract
IL279993B1 (en) Mannoside-c compounds are useful for treating urinary tract infections
IL279260A (en) KDM1A inhibitors for the treatment of diseases
ZA202001721B (en) Chromane monobactam compounds for the treatment of bacterial infections
IL271863B (en) Compounds and their use for the treatment of microbial infections
IL276482A (en) Compounds for pain management
IL250596A0 (en) The composition for the treatment and prevention of urinary tract infections
HUE064253T2 (hu) Emulziók hüvelyi fertõzések kezelésére
EP3426671A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
IL276413A (en) A device for the treatment of urinary tract infections
EP3866601A4 (en) ORGANOSILANES TO TREAT AN INFECTION
IL271236A (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
EP4121403A4 (en) NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS
EP3958754C0 (fr) Dispositif pour le traitement de la maladie hemorroïdaire
GB2591598B (en) Composition for the treatment of urinary tract infections
IL258683A (en) Gel-based compositions for treating urinary tract infections
EP3890731A4 (en) COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION
EP3773221A4 (en) TREATMENT OF HYDROCEPHALUS
SG10201405850PA (en) Composition for prevention or treatment of urinary tract infection
GB201911728D0 (en) Bacterial composistions for the treatment of disease
ZA201901948B (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
GB201813721D0 (en) Treatment of urinary tract disorders
GB201714014D0 (en) Treatment of urinary tract disorders
EP3242667C0 (en) FINAFLOXACIN FOR USE IN THE TREATMENT OF URINARY TRACT INFECTIONS
GB201523017D0 (en) The combination of chinese medicine for treating urinary tract infection